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Abstract
A diverse suite of effector immune responses provide protection against various pathogens. However, the array of effector
responses must be immunologically regulated to limit pathogen- and immune-associated damage. CD4+Foxp3+ regulatory
T cells (Treg) calibrate immune responses; however, how Treg cells adapt to control different effector responses is unclear.
To investigate the molecular mechanism of Treg diversity we used whole genome expression profiling and next generation
small RNA sequencing of Treg cells isolated from type-1 or type-2 inflamed tissue following Leishmania major or
Schistosoma mansoni infection, respectively. In-silico analyses identified two miRNA ‘‘regulatory hubs’’ miR-10a and miR-182
as critical miRNAs in Th1- or Th2-associated Treg cells, respectively. Functionally and mechanistically, in-vitro and in-vivo
systems identified that an IL-12/IFNc axis regulated miR-10a and its putative transcription factor, Creb. Importantly, reduced
miR-10a in Th1-associated Treg cells was critical for Treg function and controlled a suite of genes preventing IFNc
production. In contrast, IL-4 regulated miR-182 and cMaf in Th2-associed Treg cells, which mitigated IL-2 secretion, in part
through repression of IL2-promoting genes. Together, this study indicates that CD4+Foxp3+ cells can be shaped by local
environmental factors, which orchestrate distinct miRNA pathways preserving Treg stability and suppressor function.
Citation: Kelada S, Sethupathy P, Okoye IS, Kistasis E, Czieso S, et al. (2013) miR-182 and miR-10a Are Key Regulators of Treg Specialisation and Stability during
Schistosome and Leishmania-associated Inflammation. PLoS Pathog 9(6): e1003451. doi:10.1371/journal.ppat.1003451
Editor: Andrew N. McKenzie, University of Cambridge, United Kingdom
Received February 6, 2013; Accepted May 7, 2013; Published June 27, 2013
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was funded by NIAID, NIH Intramural Programme and National Institute for Medical Research, MRC (MRC File Reference number
MC_UP_A253_1028). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mwilson@nimr.mrc.ac.uk
. These authors contributed equally to this work.
Introduction
Regulatory T (Treg) cells [1] employ an arsenal of non-
overlapping mechanisms to maintain immunological homeostasis
at environmental interfaces [2] and internal organs [3], preventing
the development of hyper-inflammatory conditions [4,5]. The
suppressive functions of Treg cells are crucial, without which fatal
lympho- and myelo-proliferative autoimmune syndromes develop
[6]. Restoring immunological homeostasis with regulatory T cell-
based therapy may remedy some hyper-inflammatory conditions
[7]. Regulatory T cells also restrict de novo responses to foreign
antigens, limiting immunopathologies but sometimes at the cost of
preventing natural, or vaccine-mediated, immunity [8]. In this
context, temporarily disarming Treg functions may increase the
efficacy of vaccines and immunity to infection. Elemental to any
Treg-based therapeutic strategy is manipulating the appropriate
Treg cells. Expression of the transcription factor forkhead box P3
(Foxp3) in ab+CD4+ lymphocytes activates and represses a suite of
target genes [9] essential for Treg development and function. For
this reason, Foxp3 expression is commonly used as a marker of
Treg cells and is often used to compare Treg cells from a variety of
different diseases. It has recently emerged that Foxp3+ Treg cells
are heterogeneous and may be as diverse as the types of immune
responses they regulate [10–14]. Foxp3+ Treg cells therefore
represent a population of loosely related lymphocytes, still
requiring greater molecular characterization.
Foxp3+ cell development and function is intricately controlled
transcriptionally by epigenetic modifications influencing gene
accessibility [15] and post-transcriptionally by microRNAs
(miRNAs) [16]. miRNAs have emerged as key regulators of innate
and adaptive immune responses [17] and confer robustness and
adaptability to cells in response to environmental fluctuation [18].
Disrupting canonical miRNA biogenesis by ablating the miRNA
processing enzymes Dicer or Drosha in T cells [19–21] dysregulated
T cell proliferation, differentiation, survival and cytokine produc-
tion leading to a reduction in Foxp3+ cells and subsequent lethal
inflammation [19]. Deletion of the entire miRNA repertoire
specifically within Foxp3+ cells phenocopied Foxp32/2 mice with a
loss of Treg function and the development of fatal autoimmunity
[22,23]. These studies highlight the crucial role of miRNA-
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mediated gene regulation in Treg biology. However, which
miRNAs are required for different Tregs and Treg-associated
functions is poorly understood.
Several miRNAs (miR-21, miR-31, miR-24 and miR-210)
[24,25] directly target Foxp3 in human T cells, regulating Foxp3
expression and Treg development. Additionally, Foxp3 activates
miRNA-mediated mechanisms [25] to repress effector pathways,
including suppression of SOCS1 via induction of miR-155 [26].
These studies indicate an intricate functional relationship between
Foxp3 and miRNAs. Furthermore, Lu and colleagues [27]
recently identified a role for miR-146a in regulating the expression
of Stat1, which is required for Treg-mediated control of Th1
responses. While such individual miRNA:target interactions are of
interest, a single miRNA can target hundreds of mRNAs [28],
simultaneously regulating multiple pathways.
We hypothesized that widespread miRNA-mediated regulation
contributes to Foxp3+ cell diversity. To test this, we isolated
Foxp3+ cells from mice chronically infected with Schistosoma
mansoni, a parasitic helminth that invokes a polarised Th2
response, or Leishmania major, a parasitic protozoa controlled by
Th1-mediated immunity. Microarray analysis revealed dramati-
cally different gene expression profiles, confirming the heteroge-
neity of Foxp3+ cells. To investigate which miRNAs contribute to
the observed gene expression differences, we first deep sequenced
the small RNAome from these two Foxp3+ populations and
identified several miRNAs that were significantly differentially
expressed, relative to Treg cells taken from naı̈ve mice. These
miRNAs were analyzed further using our recently published in
silico method [29] for predicting candidate ‘regulatory hubs’. miR-
10a was identified as the strongest such regulatory hub in L. major
Foxp3+ cells, whereas miR-182 was the most critical in S. mansoni
Foxp3+ cells. Gain and loss of function experiments in vitro and in
vivo using primary Foxp3+ cells and Foxp3+ cells isolated from
Th1 or Th2 inflamed tissue confirmed many of the predicted
targets and functions for miR-10a and miR-182. We further
demonstrated that IL-4 up-regulates miR-182, potentially through
the transcription factor cMaf, which is also up-regulated by IL-4.
miR-182 critically restricted IL-2 production, possibly by its
control of Bach2 [30] and Cd2ap [31]. We also showed that IL-12/
IFNc represses both miR-10a and its candidate upstream
transcription factor Creb. Reduced miR-10a correlated with an
increase in miR-10a target genes, Nr4a3 and Fbxo30, which have
previously been shown to control IFNc. Collectively, this study
supports the concept of heterogeneity, or plasticity, within the
Foxp3+ pool and identifies candidate ‘regulatory hub’ miRNAs,
miR-10a and miR-182, which control IFNc and IL-2 through
essential gene programs.
Results
Foxp3+ Regulatory T cells employ distinct gene programs
during chronic Th2-associated (S. mansoni) or Th1-
associated (L. major) infection
Following infection with Schistosoma mansoni or Leishmania major,
robust Th2 or Th1- responses develop [32,33], accompanied by
the recruitment of Foxp3+ Treg cells [34–39]. Genome-wide
analysis of isolated Foxp3+ cells recruited to the liver of S. mansoni
(S. mansoni Foxp3+) or ear of L. major (L. major Foxp3+) infected mice
(Fig. 1A) identified distinct gene expression profiles, relative to
Foxp3+ cells isolated from the spleen of uninfected mice (Fig. 1B).
Of the differentially expressed genes, 185 (11.6%) were common
between L. major and S. mansoni, whereas 441 (27.7%; S. m.) and
967 (60.7%; L. m.) were specific to each population (Figure 1C),
indicating that, with respect to gene expression, these Foxp3+
populations were substantially different from one another. The
vast majority of the 185 common genes (Table S1) were similarly
regulated in each Treg population (Figure S1). Relative to
Foxp3+ cells from the spleen of uninfected mice, L. major Foxp3+
cells upregulated several heat shock proteins (Hsph1, Hspa8 and
Hspa1a), cytokine and chemokine-associated genes (Il23r, Il33,
IL18R1, Tgif1, Cxcl10, Rgs2, Lph2, Tnfaip3) and a range of
transcriptional regulators (Bcl6, Mxi1, Atf3, Ror-a, Rel, Irf4, Stat5a,
Tfap2a) (Figure 1 D). S. mansoni-derived Foxp3+ cells, in contrast,
upregulated genes associated with inhibition and killing (Gp49a,
Klrg1, Gzma, Nkg7, Lag3, Tigit Cd200r1 and Cd200r1l, Trail
(Tnfsf10)), integrins and adhesion molecules (Alcam, Epcam, Itga1,
Itgb8, Selplg (P-Selectin)), cytokines and chemokines (Csf1, Il10r1,
Il12rb2, Il18rap, Il1rn, Tgfbr1, Socs2, Ccl5, Ccl1, Ccl3l, Cxcl3, Cxcr6,
Cxcr3, Ccr1), and different transcriptional regulators (Tbx21, Pparc
and Irf8) (Figure 1E), many of which were also observed in a
previous report [36].
Deep sequencing of small RNA species reveals distinct
miRNA profiles between Foxp3+ cells isolated from
chronic helminth (S. m.) or protozoan (L. m.) infection
To identify miRNAs that might contribute to the different
expression profiles, we deep sequenced small RNA species from
each of the three Foxp3+ populations (S. m., L. m. and Naı̈ve) and
obtained 12–22 million reads in each sample (Table. S2). Within
S. mansoni Foxp3+ cells, 31 miRNAs were differentially expressed
(p,0.05) (Figure 2A and Table. S3). HIF1a-inducible miR-210
and 2 poly-cistronic miRNAs, miR-183 and IL-2-inducible miR-
182, were the most significantly up-regulated (Figure 2A).
Seventeen miRNAs were differentially regulated (p,0.05) in L.
major Foxp3+ cells. Only one of these miRNAs, miR-100, was up-
regulated; while miR-32 and miR-10a were the two most
significantly down-regulated (Figure 2C and Table. S3).
Notably, down-regulation of miR-10a in L. major Foxp3+ cells
was relative to ‘naı̈ve’ Foxp3+ Treg cells, and not relative to naı̈ve
T cells, as recently reported [40]. Several miRNAs were
differentially expressed in both Foxp3+ populations, including
miR-151, miR-30e, miR-15b, miR-132, miR-342, miR-10a and
Author Summary
The diversity of pathogens that the immune system
encounters are controlled by a diverse suite of immuno-
logical effector responses. Preserving a well-controlled
protective immune response is essential. Too vigorous an
effector response can be as damaging as too little.
Regulatory T cells (Treg) calibrate immune responses;
however, how Treg cells adapt to control the diverse suite
of effector responses is unclear. In this study we
investigated the molecular identity of regulatory T cells
that control distinct effector immune responses against
two discrete pathogens, an intracellular parasitic protozoa,
Leishmania major, and an extracellular helminth parasite,
Schitsosoma mansoni. The two Treg populations studied
were phenotypically and functionally different. We identi-
fied molecular pathways that influence this diversity and
more specifically, we identified that two miRNAs (miR-182
and miR-10a) act as ‘‘regulatory hubs’’ critically controlling
distinct properties within each Treg population. This is the
first study identifying the upstream molecular pathways
controlling Treg cell specialization and provides a new
platform of Treg cell manipulation to fine-tune their
function.
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Figure 1. Differential gene expression in CD4+Foxp3+ cells isolated from chronic S. Mansoni or chronic L. Major infected tissue. (A)
Isolation and FACS sorting of CD4+Foxp3+ cells from the liver of S. Mansoni or ear of L. Major infected mice. (B) Heat map of differential gene
expression showing biological replicates (naı̈ve Treg = 7, S. m. Treg = 4, L. m. Treg = 3 biological replicates) for the isolated Foxp3+ populations. 3944
array probes were differentially expressed at a false discovery rate (FDR) less than 0.05. The list of 3944 array probes is provided in Table S1. (C)
Number of common (overlap) and unique genes that were differentially regulated between the Sm-Foxp3+ cells and Lm Foxp3+ cells, relative to
‘Naı̈ve’ Foxp3+ cells (FDR,0.1 and fold change .1.5). (D) Immunity-associated genes up-regulated in Lm Foxp3+ cells. (E) Immunity-associated genes
up-regulated in and Sm Foxp3+ cells.
doi:10.1371/journal.ppat.1003451.g001
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Figure 2. Differentially expressed miRNAs and candidate miRNA regulatory hubs in Th1- and Th2-Treg cells. miRNAs with significantly
altered expression following (A) Schistosoma mansoni (Sm) or (C) Leishmania major (Lm) infection (Student’s t-test p-value,0.05); y-axis: log (fold-
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miR-32; however, not always in the same direction. For example,
miR-132, which regulates interferon-stimulated genes [41], was
,2-fold up-regulated in S. mansoni Foxp3+ cells, but ,6-fold down
regulated in L. major Foxp3+ cells.
We next employed in silico Monte Carlo simulation analyses to
identify which, if any, of the up- or down-regulated miRNAs in
each Foxp3+ population are predicted to target significantly more
of the down- or up-regulated mRNA transcripts, respectively, than
expected by chance (i.e. ‘regulatory hub’ miRNAs) [29]. This
approach identified miR-182 (up-regulated in S. mansoni Foxp3+
cells) as the strongest candidate regulatory hub of the network of
down-regulated genes in S. mansoni Foxp3+ cells (Figure 2B and
Table S4), and miR-10a (down regulated in L. major Foxp3+ cells)
as the strongest candidate regulatory hub of the network of up-
regulated genes in L. major Foxp3+ cells (Figure 2D).
miR-182 and miR-10a target distinct, non-overlapping
genes in Foxp3+ cells
To validate the predicted target genes of miR-182 and miR-
10a, we isolated primary Foxp3+ cells (predominantly nTreg cells),
over-expressed or inhibited miR-182 or miR-10a using miRNA
mimics or hairpin inhibitors, and measured miRNA and target
mRNA expression. Transfection at .80% efficiency (Figure S2)
increased (20-fold) or decreased (10-fold) miR-182 using specific
mimics or inhibitors (Figure 3A). In contrast to naı̈ve T cells [42],
expression of a previously reported miR-182 target, Foxo1, was
only marginally regulated by miR-182 in Treg cells failing to reach
statistical significance (Figure 3A, boxed). Of the 14 predicted
targets in S. mansoni Foxp3+ cells (Table S5), 6 were significantly
regulated (.1.5 fold) in response to miR-182 mimics or inhibitors.
Similarly, miR-10a significantly regulated Hoxa1, a previously
validated miR-10a target [43], along with 7 of the 11 genes in L.
major Foxp3+ cells predicted to be targets of miR-10a (Figure 3B
and Table S5). Collectively, using gain and loss of function for
miR-182 and miR-10a in primary Foxp3+ cells, these data identify
that miR-182 regulates 6 of the predicted genes identified in Th2-
Treg cells and miR-10a regulates 7 of the predicted genes
identified within Th1-Foxp3+ cells.
Foxp3+ Treg cells recruited to Th2 or Th1-mediated
airway inflammation up-regulate miR-182 and down-
regulate miR-10a, respectively
To validate the functional significance of these miRNA:target
interactions, and to determine whether differential expression of
miR-182 and miR-10a was restricted to Foxp3+ cells from S.
mansoni and L. major infections, we developed a Th1 and Th2-
driven airway inflammation model. This system allowed us to
eliminate pathogen influences, tissue-specific responses and any
other factors that may have contributed to the observed Treg
profiles observed above. Briefly, naı̈ve T cells
(CD4+CD44loCD62LhiCD252) from congenic and transgenic
C57BL/6 mice (CD45.1+OTII+RAG22/2) were polarized in
vitro under Th1 or Th2 conditions, secreting high levels of IFNc
or IL-5 respectively (Figure 4A), and adoptively transferred into
C57BL/6 CD45.2 Foxp3gfp mice. One-day prior to transfer (d-1)
and one and three days following transfer (d1 and d3), recipient
mice received an intra-tracheal delivery of OVA into the lower
airways (Figure 4A). Adoptively transferred cells migrated to the
lung and broncho-alveolar (BAL) spaces (Figure 4B) and caused
peri-bronchial and peri-vascular inflammation (Figure 4C).
Antigen recall assays demonstrated that recipients of Th1 cells
produced IFNc and IL-10 (Figure 4D) and increased the
expression of Inos, Mig (Cxcl9) and Ip-10 (Cxcl10) within the lung
(Fig. 4E). Mice that received Th2 cells secreted IL-4, IL-5 and IL-
9 (Figure 4D) and up-regulated Arg1, Eotaxin (Ccl11) and Gob5
(Clca3) within the lung (Figure 4E), characteristic of Th1 or Th2-
mediated airway inflammation. CD4+Foxp3+ cells isolated from
Th1- or Th2-inflammed lungs (Figure 4F) up-regulated Tbx21,
Gata3, Foxp3, Ctla4, Gitr (Tnfrsf18), Il10ra, Ebi3 and Il10 with a small
increase in Tgfb in Th1-Treg cells only (Figure 4G). As predicted,
Foxp3+ cells from Th1 inflamed lungs down-regulated miR-10a
with no change in miR-182 (Figure 4 H), similar to Foxp3+ cells
from L. major infected mice (Figure 2). Foxp3+ cells from Th2-
inflamed lungs up-regulated miR-182, with a marginal increase in
miR-10a, similar to Foxp3+ cells from mice infected with S. mansoni
(Figure 2). With the exception of Fosl and Cebpa, we also observed
a very similar target gene expression profile in Th1-Treg or Th2-
Treg cells isolated from the inflamed lung as compared to Treg
cells from L. major or S. mansoni infected mice (Figure 4I).
These data support the notion that down regulation of miR-10a
and up-regulation of miR-182 within Foxp3+ cells is associated
with Th1 or Th2 biased immune environments, respectively.
Th1-, but not Th2-, associated Treg cells can efficiently
suppress both Th1 and Th2 cells
To test whether Th1 and Th2-associated Treg cells were
functionally distinct from each other, we fluorescently-labeled
OVA-specific Th1 or Th2 Teff (CD4+CD44+Foxp32) cells
isolated from Th1- or Th2-inflamed lungs, or naı̈ve Teff cells as
a control population, and co-cultured these cells with Th1- or
Th2-Treg cells (CD4+Foxp3+) from respective Th1 or Th2-
inflamed lungs, or with Treg cells isolated from the opposing
inflammatory environment in a series of ‘cross-over’ assays. In
these assays, Th1-Treg cells potently suppressed Th1-Teff cells
(Figure S3A) and Th2-Teff cells (Figure S3B), whereas Th2-
Treg cells only suppressed Th2 cells and not Th1 cells (Figure
S3C and S3D).
miR-182 and miR-10a are required for Foxp3+ Regulatory
T cell-mediated suppression of Th2 and Th1 cell
proliferation in vitro, respectively
We next tested whether down-regulated miR-10a and up-
regulated miR-182 was functionally required for Th1- and Th2-
Treg-mediated suppression, respectively. Th1-Treg cells isolated
from the lungs of mice were transfected with miR-10a mimics
(Figure S3E), to overturn the down-regulated miR-10a observed
in Th1-Treg cells (Figure 4H). Following the observation that
miR-182 was upregulated in Th2-associated Foxp3+ cells
(Figure 4H), Th2-Treg cells were transfected with miR-182
hairpin inhibitors (Figure S3E). Mock-transfected Th1-Foxp3+
cells efficiently suppressed Th1 (Figure 5A), Th2 (Figure 5B)
and naive (Figure 5C) T cell proliferation. However, Th1-Treg
cells transfected with miR-10a mimics were compromised in their
ability to suppress Th1 cells (Figure 5A) and naı̈ve T cells
change) of miRNA expression level. Representation of predicted targets for up-regulated miRNAs among down-regulated genes following S. mansoni
(Sm) infection (B). Representation of predicted targets for down-regulated miRNAs among up-regulated genes following L. major (Lm) infection (D).
Y-axis: 2log of the empirical p-value of predicted target site enrichment over background expectation. Orange: miRNAs predicted to target
differentially expressed genes significantly more than expected by chance, full details in Table S4. Dashed line: p-value = 0.05.
doi:10.1371/journal.ppat.1003451.g002
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(Figure 5C), but retained the ability to partially suppress Th2 cells
(Figure 5B). As a further control, we transfected Th1-Treg cells
with miR-182 inhibitors, as miR-182 was not differentially
regulated in Th1-Treg cells (Figure 4H) and this did not
influence Th1-Treg mediated suppression of Th1, naı̈ve or Th2
cells (Figure 5A, B and C). Th2-Treg cells were unable to
suppress Th1 cells (Figure 5D) but were fully capable of
suppressing Th2 (Figure 5E) and naı̈ve T cells (Figure 5F).
Transfection with miR-10a mimics had no impact on Th2-Treg
mediated suppression. However, Th2-Treg cells transfected with
miR-182 inhibitors compromised their ability to suppress Th2 and
naı̈ve T cell proliferation, indicating that elevated miR-182 was
required for Th2-Treg function. Treg cells isolated from the spleen
of naı̈ve animals were unable to control OVA-specific Th1 or Th2
cells (Figure S4A and S4B), but were fully capable of suppressing
naı̈ve T cells (Figure S4C). Transfection of Treg cells from naı̈ve
mice with miR-182 inhibitors or miR-10a mimics also compro-
mised their suppressive capacity. Taken together, these data
indicate that down-regulation of miR-10a is critically required for
Th1-Treg cells to control Th1 cells and naı̈ve T cells, while up-
regulated miR-182 is required for Th2-Treg-mediated suppression
of Th2 cells and naı̈ve T cells, highlighting the divergence of these
two Treg populations, while Treg cells from naı̈ve mice were
dependent upon both tightly regulated miR-10a and miR-182.
IL-4 regulates cMaf and miR-182, while IL-12/IFNc
regulates Creb and miR-10a in natural and inducible Treg
cells
To determine the upstream factors that may contribute to miR-
182 and miR-10a expression in Treg cells, we screened for
transcription factor binding sites in the promoters of the primary
transcripts of both miR-182 and miR-10a using Pwm-Scan (as
described in the methods). We identified putative binding sites in
the miR-182 promoter for IL-4-regulated transcription factors
(TFs), including cMaf, and IL-12/IFNc-regulated TFs, including
Creb, in the miR-10a promoter (Figure S5A). Concordant with
the in-silico predictions, exposure of natural (nTreg) or in vitro
generated inducible Treg (iTreg) cells (Figure S5B) to IL-4,
mimicking a Th2 environment, up-regulated cMaf (Figure S5C),
and miR-182 (Figure S5E), similar to ex vivo Th2-Treg cells
(Figure 2, and Table S1). IL-12/IFNy treatment of nTreg and
iTreg, mimicking the Th1 environment, down-regulated Creb
(Figure S5D) and miR-10a (Figure S5F) in Treg cells, relative to
naı̈ve T cells, pheno-copying miR-10a expression in ex vivo Th1-
Treg cells (Figure 2). Following recent studies indicating that
Foxp3-mediated epigenetic modifications may be altered in
Foxp3gfp-reporter mice [44,45], we compared miR-182 and
miR-10a expression in freshly isolated nTreg cells and in vitro
generated iTreg cells from Foxp3rfp and Foxp3gfp-reporter mice,
but did not observe any appreciable difference in miR-182 or
miR-10a expression, relative to naı̈ve T cells (Figure S6).
miR-182 and miR-10a control IL-2 and IFNc in Treg cells
CD2, via Cd2ap and BACH2, regulates IL-2 production
through direct binding to the IL-2 promoter [30,31]. Following
the observation that miR-182 targeted Cd2ap and Bach2, and that
IL-4 regulated miR-182 (Figure S5), we tested whether IL-4
influenced the expression of miR-182, Bach2, Cd2ap and subse-
quent IL-2 production. IL-4 treated nTreg or iTreg cells had
reduced Bach2 and Cd2ap relative to naı̈ve T cells or untreated
Treg cells (Figure S7A, S7B). We therefore assayed for IL-2
following IL-4 treatment, to determine whether IL-4-regulated
miR-182, and subsequent changes in Bach2 and Cd2ap had any
influence on IL-2 responses. Il2 mRNA and protein levels were not
altered following IL-4 treatment alone (Figure S7E), however
inhibition of miR-182, with or without IL-4 treatment, led to a 50-
fold induction of Il2 transcription and IL-2 secretion (Figure
S7E). These data indicate that miR-182 controls IL-2 production
in Treg cells, possibly via Cd2ap and Bach2, and that IL-4 re-
enforces miR-182-mediated control of IL-2.
Previous reports have identified that Nr4a3 induces Foxp3
expression and represses IFNc [46]. Following the observation
that miR-10a targeted Nr4a3 we assayed for IFNc following miR-
10a over expression, with or without IL-12/IFNc treatment.
IL-12/IFNc treatment alone induced IFNc in Treg cells (4-fold,
Figure S7F), similar to previous reports [47,48], however IFNc
was increased 40-fold when combined with miR-10a over-
expression (Figure S7F). Interestingly, miR-10a over-expression
alone also led to an increase in IFNc (9-fold). Thus, type-2
regulated miR-182 and type-1-regulated miR-10a, respectively,
contribute to the regulation of IL-2 and IFNc responses in Th2-
and Th1-Treg cells.
Down-regulation of miR-10a and up-regulation of miR-
182 is essential for Foxp3+ Regulatory T cell-mediated
control of Th1- or Th2-driven airway inflammation,
respectively
To determine whether miR-10a and miR-182 was required for
Treg survival, migration and control of Th1 and Th2-mediated
inflammation in vivo, we designed a double adoptive transfer
system (Figure S8). Briefly, Th1- or Th2-associated Foxp3+ Treg
cells were isolated from Th1 or Th2–inflamed tissue, as above
(Figure 4). A second recipient mouse received Teff (OTII-Th1 or
OTII-Th2) cells alone or a combination of mock-transfected Treg
cells, miR-10a mimic transfected Th1-Treg cells with Th1-Teff
cells, or miR-182-inhibitor transfected Th2-Treg cells with Th2-
Teff cells. Following intra-tracheal delivery of OVA, similar
percentages of transferred Treg cells were observed in the lung of
recipient mice (Figure 6A), indicating that all Treg cells
experienced similar survival irrespective of transfection treatments.
Significant numbers of inflammatory cells were recovered from the
airspaces of mice receiving Th1 or Th2 cells (Figure 6B),
however the co-transfer of mock-transfected Treg cells significantly
reduced the number of inflammatory cells. Co-transfer of Th1
cells and miR-10a mimic transfected Th1-Treg cells, or Th2 cells
with miR-182-inhibitor transfected Th2-Treg cells failed to
suppress inflammatory cell recruitment. The requirement for
down-regulated miR-10a in Th1-Treg cells and up-regulated
miR-182 in Th2-Treg cells was also reflected by uncontrolled
IFNc or IL-5 secretion in re-stimulated lymph nodes, compared to
mice receiving mock-transfected Treg cells (Figure 6C). Mock-
transfected Treg cells potently reduced pulmonary pathology
(interstitial inflammation, mucus plugs and epithelial elongation),
which was compromised when miR-10a or miR-182 was
specifically deregulated in Th1- or Th2-Tregs, respectively
(Figure 6D). Taken together these studies highlight two diverse
Figure 3. miR-182 and miR-10a target a significant number of in-silico predicted targets in Foxp3+ Treg cells. CD4+Foxp3+ cells isolated
from naı̈ve mice and transfected with miR-182 mimics or hairpin inhibitors (A) or miR-10a mimics or hairpin inhibitors (B) to identify predicted target
gene regulation. RNA was extracted 24 hours post transfection for analysis. One of 3 individual experiments shown, with 3 biological replicates in
each experiment. p-value = 0.05. with data expressed as mean 6SEM.
doi:10.1371/journal.ppat.1003451.g003
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Figure 4. Differential miR-182 and miR-10a expression in Foxp3+ Treg cells isolated from Th2 or Th1-mediated pulmonary
inflammation. (A) Naı̈ve T cells (CD4+CD442CD62LhiCD252) from C57BL/6 CD45.1 OTII RAG22/2 were polarised under Th1 or Th2 conditions and
adoptively transferred into naı̈ve CD45.2 Foxp3gfp mice. (B) Donor cells were enumerated in the circulation (PBMC), spleen, thoracic lymph nodes
(t:LN), lung tissue and broncho-alveolar air spaces (BAL). (C) Th1- and Th2-mediated pulmonary pathology was determined in H&E stained lung
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Foxp3 populations that develop to control Th1 or Th2 inflam-
matory events. The molecular programs in these Foxp3+ Tregs are
in-part regulated by distinct upstream regulatory miRNA hubs,
miR-182 and miR-10a, which target non-overlapping and
essential genes within these diverse Foxp3+ populations.
Discussion
In this study we identified distinct populations of Foxp3+ Treg
cells recruited to Th1 or Th2 inflammatory environments
expressing unique gene and miRNA profiles. Several genes and
miRNAs were comparably regulated between the two subsets
including miR-30e, miR-15b, miR-32, miR-151 and miR-342,
with other miRNAs highlighting a clear divergence. For example
miR-132 was significantly down regulated in Foxp3+ cells from
Th1 rich surroundings (22.56 fold) and up regulated in Foxp3+
cells in Th2 environments (+2.09 fold). Using miRNA target
prediction algorithms and Monte Carlo simulations we identified
two miRNA regulatory hubs that target multiple genes contrib-
uting to the divergent gene expression profiles. Specifically, Th1
inflammation, following chronic L. major infection or acute Th1-
induced inflammation, recruited Foxp3+ Treg cells that up-
regulated a suite of genes regulated by miR-10a. In contrast,
Foxp3+ cells isolated from Th2 environments following chronic S.
mansoni infection or acute Th2-driven inflammation down-
regulated a suite of genes under the control of miR-182. These
data support the notion that Foxp3+ cells are heterogeneous, or
adaptable to their inflammatory environment [10–12,14,49] and
provide an upstream molecular mechanism contributing to
Foxp3+ heterogeneity.
Previously, T-bet has been singled out as a co-transcription
factor required for Treg cells to control anti-mycobacterial Th1
responses [12]. In our studies, Foxp3+ cells isolated from L. major
infected tissue did not up-regulate T-bet, which may be explained
by different infections, different stages of infection or different
tissues studied. In support of the latter, and in agreement with the
previous study, Foxp3+ cells isolated from Th1-inflamed lung
tissue up-regulated T-bet (,20-fold, Figure 4G), similar to
pulmonary M.Tb. Foxp3+ cells. Interestingly, T-bet was greater
than 200-fold up-regulated in Foxp3+ cells isolated from Th2-
driven inflammation or from the liver of S. mansoni infected mice
(2.6-fold). If Foxp3+T-bet+ cells are potent suppressors of Th1
responses, it is tempting to speculate that Foxp3+T-bet+ cells
contribute to a dominant Th2 environment by potently suppress-
ing Th1 responses. Similarly, Irf4, a transcription factor involved
in several T helper cell subsets [50,51], was recently identified in
Foxp3+ cells restraining Th2 responses. Irf4 however was not up-
regulated in Th2-associated Treg cells isolated from schistosome
infected mice, relative to Foxp3+ cells from the spleen of naı̈ve
mice, and was only slightly up regulated in Th1-associated Foxp3+
cells (1.68-fold). Strinkingly, Th1- Foxp3+ cells up-regulated a
collection of transcriptional regulators, including Stat-3 (1.98 fold),
Bcl6 (1.80-fold), Ap1 (2.14 fold) and Runx2 (2.02 fold). Similarly,
Th2-derived Foxp3+ cells co-expressed Blimp1 (3.78 fold), Tbx21 (T-
bet) (2.64), Hif2a (2.08 fold), E4bp4 (1.91 fold), Runx2 (1.68 fold)
and Egr2 (1.60 fold). These data suggest that there is either
significant heterogeneity, or plasticity, within Foxp3+ populations
[52] or that co-opting multiple transcription factors is common
and does not restrict control to one particular T helper subset, but
rather broadens regulatory function. Indeed, Treg cells isolated
from Type-1 inflamed tissue had the capacity to suppress Th1 and
Th2 cells, while Th2-Treg cells could only control Th2 cells. We
hypothesize that suppression of Th2 cells by Th1-Treg cells could
be mediated by TGF-b, which was slightly elevated in Th1-, but
not Th2-, Treg cells (Figure 4G) and can potently inhibit Th2
cells [53]. However, given that TGFb is highly regulated post-
translationally, surface bound or secreted bioactive TGFb may not
be increased. Alternatively, the continued ability of Th1-Treg cells
to control Th2 cells, but not Th1 cells, following over-expression of
miR-10a, is most likely due to the increased IFNc, which can also
inhibit Th2 cell responses.
Computational analysis [29] identified miR-182 in Th2-Foxp3+
cells and miR-10a in Th1-Foxp3+ cells as potential regulatory
miRNA hubs, which targeted multiple differentially regulated
genes. We focused on miR-182 and miR-10a for functional
studies, as these were the top candidate regulatory hubs from the
Monte Carlo analyses in Foxp3 cells from infected mice. In
support of this, down regulated miR-10a and up-regulated miR-
182 was also observed in Foxp3+ cells isolated from Th1- or Th2-
inflammed lungs, analogous to the chronic infection studies.
It was recently demonstrated that IL-2/STAT5 regulated miR-
182 in helper and regulatory T cells [42] targeting Foxo1 and
permitting helper cell proliferation. Despite the high consumption
of IL-2 by Foxp3+ T cells and the requirement for Foxo1, and Foxo3,
for Treg cell survival and function [54,55], a role for miR-182 in
Treg cells was not thoroughly investigated. Our systematic
approach identified putative binding sites in the promoter of
miR-182 for the IL-4-regulated transcription factor, cMaf. In
agreement with this, IL-4-treated Treg cells up-regulated cMaf,
similar to previous reports in macrophages and T cells [56,57].
Unlike naı̈ve T cells, which produce IL-4 and IL-2 and up-regulate
cMaf following IL-4 treatment, Treg cells did not produce IL-4
(data not shown) or IL-2, in part through a miR-182-dependent
pathway. The phosphorylation state of cMaf, additional pathways
including IL-2 [42] and other transcriptional regulators may also
contribute to miR-182, as cMaf transcript levels in untreated iTreg
and nTreg were indistinguishable from naive T cells, despite
elevated miR-182. Nevertheless, IL-4-treated Treg cells up-
regulated cMaf and miR-182, in line with other studies identifying
that IL-4-treated human [58,59] and murine [60] Treg cells
develop distinct and potent suppressive phenotypes. The precise
mechanism from these studies, however, was unclear.
It has long been appreciated that anergic and regulatory T cells
do not produce IL-2, through reduced JNK and ERK signaling
[61] and remodeling of the Il2 locus [62]. We identified two miR-
182-regulated genes that can control IL-2 production, Bach2, a
basic leucine zipper transcription factor [30] and Cd2ap [31]. As
predicted, the up-regulation of cMaf and miR-182 by IL-4 led to a
reduction of Bach2 and Cd2ap expression in Treg cells (Figure S5),
with no IL-2 production. Disrupting this pathway, through
inhibition of miR-182, led to an increase in Bach2 and Cd2ap
and a significant increase in transcription and secretion of IL-2,
indicating that IL-2 is critically regulated by miR-182, potentially
via control of Bach2 and Cd2ap. Although other important
molecular pathways are under the control of miR-182, including
sections. (D) PBMC, splenocytes and local lymph nodes were re-stimulated with OVA for 3 days with cytokines measured in the supernatant after 3
days. (E) RNA was isolated from pulmonary tissue and gene expression analysed by qRT-PCR and expressed as fold change relative to naı̈ve mice. RNA
was isolated from recipient CD4+Foxp3gfp+ cells (F) with mRNA (G and I) and miRNA (H) expression analysed by qRT-PCR and expressed relative to
RNA isolated from CD4+Foxp3gfp+ cells from naı̈ve mice. Data expressed as mean 6SEM. Data presented in A, B and G are representative of one of
three individual experiments..
doi:10.1371/journal.ppat.1003451.g004
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Figure 5. Up-regulated miR-182 and down-regulated miR-10a expression in Th2- and Th1-Treg cells Treg cells confers suppressive
capacity in vitro. Th1 (A & D) or Th2 (B & E) T effector (Teff, CD4+CD44+Foxp3gfp2) and Th1-Treg (A, B & C) or Th2-Treg (D, E & F) (CD4+Foxp3gfp+)
cells were isolated from the lungs of recipient mice, as in Figure 4. As a control, naı̈ve T cells (C & F) were also isolated from the spleen of OTII mice.
Teff or naı̈ve T cells (104) were labeled with cell trace violet (Invitrogen) and cultured alone, or in equal ratios (1:1) with mock transfected Treg cells,
Treg cells transfected with miR-10a mimics or Treg cells transfected with miR-182 inhibitors, as indicated, for 3 days with irradiated splenocytes
(26105) and OVA (10 mg/ml). One of 3 individual experiments is shown, with technical replicates shown in the scatter plot. Add statistical test results?
doi:10.1371/journal.ppat.1003451.g005
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those controlled by C/EBPa, Arhgef3 and Hdac9 which are also
intimately involved in Treg biology [63–66], together with
previous reports, we propose that IL-2 and IL-4 reinforce a
negative feedback loop in Treg cells, with IL-2 induced [42] and
IL-4-re-enforced miR-182 inhibiting IL-2 secretion.
miR-10a was up-regulated in ex vivo Treg cells and naı̈ve T
cells polarized into iTreg with TGFb in vitro [40,67]. We also
observed an increase in miR-10a in ex vivo nTreg and iTreg
cultures, relative to naı̈ve T cells. However, our study design
identified that miR-10a was subsequently reduced in Treg cells in
Figure 6. Up-regulated miR-182 and down-regulated miR-10a expression in Foxp3+ cells is required for Th2-Tregs to suppress Th2
response and Th1-Tregs to suppress Th1 response in vivo, respectively. In vitro-polarised Th1 or Th2 T effector (Teff) cells were adoptively
transferred with Th1-Treg (CD4+Foxp3gfp+) or Th2-Treg isolated from the lungs of mice with Th1 or Th2-driven pulmonary inflammation, respectively
and as indicated. Co-transferred Foxp3+ Treg cells were either mock transfected or transfected with miR-10a mimics or miR-182 inhibitors, as
indicated. (A) Recruitment of donor Treg cells to the lungs of recipient mice, as a percentage of total CD4+ cells in the lung. (B) Broncho-alveolar
infiltrates of mice one day following final OVA challenge. (C) Local lymph nodes were isolated and re-stimulated with OVA. IFNc or IL-5 was measured
in the supernatants after 3 days. (D) Lungs were removed, sectioned and stained with H&E for pathology. One of 2 individual experiments shown. p-
value = 0.05 with data expressed as mean 6SEM.
doi:10.1371/journal.ppat.1003451.g006
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Th1 environments. Whether splenic nTreg cells migrate to
peripheral sites or de-novo iTreg cells respond to inflammatory
events is unclear. To investigate the pathways involved in miR-10a
regulation, we identified several putative TF binding sites in the
miR-10a promoter, including the TGF-b [68], IL-2 [69], IL-12
[70] and IFNc [71]-regulated transcription factor, CREB. CREB
stabilizes Foxp3 in Treg cells [72] and is inhibited by IFNc
[71,73,74]. Creb expression was slightly elevated in ex vivo nTreg
and in vitro-generated iTreg cells, relative to naı̈ve T cells, but was
successively decreased, below naı̈ve T cell levels, following
exposure to type-1 inflammatory signals, IL-12 and IFNc.
Furthermore, miR-10a followed a similar expression pattern as
Creb, with reduced miR-10a following IL-12/IFNc treatment,
suggesting that Creb expression may influence miR-10a. Although
multiple factors can influence miR-10a and Creb expression, these
data indicate that Treg cells undergo dynamic molecular
modifications upon exposure to various inflammatory signals, in
this case along an IL-12/IFNc, Creb, miR-10a axis.
We identified several miR-10a-regulated genes in Foxp3+ cells,
including Arrdc, an a-arrestin family member that degrades
phosphorylated integrin b4 (CD104) [75] and b2-adrenergic
receptors [76], two pathways required for the development [77]
and survival [78] of Foxp3+ T cells. miR-10a also regulated the
transcriptional repressor, Bcl6, an important pathway recently
identified in iTreg cells, preventing iTreg conversion in to TFH
cells [40]. Furthermore, co-expression of Bcl6 with Blimp1, Cxcr5
and PD-1 (Pdcd1) in Foxp3+ in Treg cells identified as TFH-Reg
cells, have also been reported [11,13]. Dissimilar to these studies
we did not observe a TFH-Reg, or TFH phenotype, as phenotypic
markers of TFH cells, beyond Bcl6, were reduced or unchanged
(Cxcr5 23.22-fold, Btla 22.0 fold, unchanged Il21, Cd40l, Cd200,
Cd30l, Cd57, and Fyn). The relatively subtle changes in miR-10a
and Bcl6 in Th1-Treg cells may retain Treg function, without
conversion into TFH cells, or TFH-Reg cells. For example, we
observed that miR-10a was reduced 3.5-fold in Th1-Treg relative
to naı̈ve Treg cells, in contrast to the study identifying iTreg cell
conversion into TFH cells [40] when iTreg cells were transduced
with a miR-10a sponge to significantly sequester miR-10a.
Similarly, we observed a relatively subtle increase in Bcl6 (1.79-
fold, Table S1) compared to the ,10-fold increase in TFH-Reg
cells [11,13].
In addition to Bcl6, we identified Fbxo30 (also known as Fbxw7
and Fbw7) and the TGFb-signaling molecule, Nr4a3 [79,80] as
miR-10a-regulated genes in Th1-Treg cells. Conditional deletion
of Fbxw7 in CD4+ cells [81], or deletion of Nr4a3 and the closely
related Nr4a1, resulted in hyper-proliferation of T cells, thymic
lymphoma’s and lethal lymphoproliferation [82], a phenotype
similar to Foxp32/2 mice. Furthermore, ectopic expression of
Nr4a3 induced Foxp3 expression and repressed IFNc production
[46]. IL-12/IFNc treatment, which reduced Creb and miR-10a
expression, resulted in a small increase in miR-10a-regulated
genes, Fbxo30 and Nr4a3 and a small increase in Ifnc
transcription. Similar observations have been made in mouse
and human Treg cells, with IL-12-treatment converting Foxp3+
cells into IFNc+Foxp3+ cells [47,48]. Disrupting this molecular
pathway, by over-expressing miR-10a, coupled with IL-12/IFNc
treatment, dramatically increased Ifnc transcription, indicating
that reduced miR-10a permitted tight control over IFNc in Treg
cells, possibly via Nr4a3 [46]. IFNc secretion by Th1-Treg cells
transfected with miR-10a mimics provides a plausible explanation
as to how Th1-Treg cells retained their ability to partially control
Th2 cells following miR-10a manipulation. Collectively, we have
identified a suite of miR-10a targets in Th1-Foxp3+ cells, which
regulate G-protein coupled receptor function (Aardc3), gene
transcription (Bcl6), ion transport (Clcn5 and Rap2a), iron
metabolism (Tfrc) and TGF-b signaling (Fbxo30/Fbxw7 and
Nr4a3). Furthermore, we have identified a mechanistic pathway
of IL-12/IFNc-regulated miR-10a expression that critically
controls IFNc production in Treg cells.
In summary, Th1- or Th2-associated Foxp3+ cells developed
distinct molecular profiles, influenced by local cytokine signaling
pathways. IL-12/IFNc-influenced miR-10a controlled subsequent
IFNc production in Th1-Treg cells, while IL-4-regulated miR-182
critically prevented IL-2 production in Th2-Treg cells. In addition,
we propose that miR-182 and miR-10a function as regulatory
hubs, coordinating a variety of pathways in Th2-Treg and Th1-
Treg cells. These data strongly support the concept that different
Foxp3+ cells activate distinct gene programs, shaped by different
inflammatory signals. We also provide evidence for an upstream




Female C57BL/6, C57BL/6 CD45.2 Foxp3gfp [83], C57BL/6
Foxp3rfp [84], C57BL/6 CD45.1 OTII RAG22/2 6–8 weeks’ old
were bred and kept in the specific pathogen–free facility at the
National Institute for Medical Research, or National Institutes of
Health.
Ethics statement
All animal experiments were approved by UK National
Institute for Medical Research Ethical Review Panel and NIAID
animal care and use committee and carried out according to
institutional guidelines (UK National Institute for Medical
Research Ethical Review Panel), UK Home Office regulations
(Project licence no. 80/2506) and according to The NIAID animal
care and use committee in accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. A minimum of 5 mice per group was
used in each experiment, unless indicated.
Parasites and experimental infections
Percutaneous infections were carried out with 35 S. mansoni
cercariae (Biomedical Research Institute, Rockville, MD), as
previously described [85]. Mice were infected in the ear dermis
with 105 L. major metacyclic promastigotes using a 27.5 G needle in
a volume of 10 ml [38].
FACS sorting, staining and analysis
Cells were isolated from infected or inflamed tissue by
mechanical disruption followed by percoll gradient separation
and were stained with anti-mouse CD4 (RM4-5, BD Biosciences,
Pacific Blue (V450) or APC), CD3e (17A2, BD Biosciences, FITC
or Alexa flour 700), CD44 (IM7, BD Biosciences, PE-Cy7 or Alexa
flour 700), CD25 (PC61, BD Biosciences, PE or FITC) and
CD45.1 (A20, BD Biosciences, APC or PE) diluted in PBS with
0.1% FCS before analysis using a BD LSRII and TreeStar FlowJo.
In-vitro suppression assay
For proliferation/suppression assays, 104 Teff cells were labeled
with cell trace violet (Invitrogen) as per manufacturers guidelines
and stimulated with irradiated splenocytes (26105) and OVA
(10 mg/ml) for 3 days in the presence or absence of Treg cells, at
the indicated ratios before analysis using a BD LSRII and
TreeStar FlowJo.
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RNA extraction, microarray and Next Generation
sequencing
FACS purified cells were stored in RLT lysis buffer at 280uC
until RNA was extracted. For mRNA analysis, RNA was extracted
using RNeasy spin columns (Qiagen) followed by DNAse
treatment. cDNA was generated from 5 ng of total RNA using
WT-Ovation Pico system (version 1) RNA Amplification System
followed by double stranded cDNA synthesis using WT-Ovation
Exon Module. cDNA quality was determined using an Agilent
BioAnalyzer and through hybridization performance on Affyme-
trix GeneChip mouse gene 1.0 ST arrays. For miRNA analysis,
small RNA species (20–200 bp) were collected from the same
samples and used for sequencing on the ABI SOLiD sequencer
(Applied Biosystems, Santa Clara, CA). Hybridization, fluidics and
scanning were performed according to standard Affymetrix
protocols (http://www.affymetrix.com). GeneChip Operating
Software (GCOS v1.4, http://www.Affymetrix.com) was used to
convert the image files to cell intensity data (cel files). The array
data were quantile normalized and analyzed using Partek
Genomics Suite software (Partek, inc. St. Louis, Mo., v6.4-
6.09.0129). We identified differentially expressed genes using
ANOVA and t-tests. Genes with false discovery rate corrected p-
values less than 0.1 and fold change values $1.5 were considered
significant. The resulting data were analyzed with IPA (Ingenuity
Pathway Systems, www.ingenuity.com). Libraries for SOLiD
sequencing were prepared using the SOLiD Small RNA
Expression Kit (Applied Biosystems) following the manufacturer’s
protocol. Templated beads for sequencing were prepared using a
1 pM library input following the Applied Biosystems SOLiD 3
Templated Bead Preparation Guide (Applied Biosystems, Foster
City CA). Small RNA libraries were run on the ABI SOLID 3.0.
Reads were mapped to Mus musculus microRNAs (miRBase
v13.0) [86] using the Small RNA Analysis Tool v0.4 (Applied
Biosystems). Read counts below 25 (including miR-96) were
removed from further analysis with read counts between samples
normalized based on the total number of uniquely mapped reads
in each sample.
Identification of miRNA regulatory hubs
Candidate miRNA regulatory hubs were identified using Monte
Carlo simulation analysis as described previously [29]. First, we
used the seed-based target prediction algorithm TargetScanS to
determine for each miRNA the number of predicted targets
among our gene set of interest (e.g. up/down-regulated transcripts
in Foxp3+ cells in response to pathogen). We repeated this
procedure 10,000 times with a new set of randomly selected genes
from the genome each time, in order to generate a background
expectation of the number of predicted target genes for each
miRNA, which was then used to calculate an empirical p-value for
the number of predicted target genes in the gene set of interest. To
account for differences in the average 39 UTR length between the
genes of interest and the randomly selected genes in each
simulation, the number of predicted target genes was normalized
to the average 39 UTR length.
Prediction of transcription factor binding sites
The genomic locations of the miR-182 and miR-10a transcrip-
tion start sites (TSS) were identified using previously published
methods [87,88]. We defined the promoter region as 1 kb
upstream and 500 bp downstream of the TSSs. Within these
promoters, we identified putative transcription factor binding sites
using PWMSCAN [89], which searches for sequences that match
any known transcription factor binding site motif recorded in
TRANSFACv10.2. A match score with a p-value,561026 was
considered to be a high-confidence binding site prediction.
Quantitative RT-PCR for mRNA and miRNA
RNA was isolated using RNeasy mini spin columns followed
by miScript RT or Quantitect RT according to manufacturer’s
recommendations (Qiagen). Real-time RT-PCR was performed
on an ABI Prism 7900HT Sequence Detection System (Applied
Biosystems) with relative quantities of mRNA determined using
SYBR Green PCR Master Mix (Applied Biosystems) and by the
comparative threshold cycle method as described by Applied
Biosystems for the ABI Prism 7700/7900HT Sequence Detec-
tion Systems. mRNA levels were normalized to HPRT and
miRNA levels were normalized to RNU6B and then expressed
as a relative increase or decrease compared with levels in
controls.
miRNA mimic and hairpin inhibitor transfection
Treg cells were isolated, as described above and transfected with
100 nM of miR-182 or miR-10a mimics or hairpin inhibitors
(Thermo Scientific Dharmacon) or MOCK transfected using
Nucelofection reagents according to manufacturer’s recommen-
dations (Amaxa). Ex-vivo nTreg cells were cultured in rIL-2
(10 ng/ml)-supplemented media for 24 hours before washing and
use in suppression assays or transfer in-vivo. BlockiT fluorescent
oligos (Invitrogen) were used to determine transfection efficiency.
miRNA mediated impacts on mRNA expression was determined
24–48 hours post transfection.
T cell polarisation, adoptive transfer, airway inflammation
model
Naı̈ve T cells (CD4+CD442CD62LhiCD252) were FACS
purified and polarised under Th1 (IL-12, 10 ng/ml; anti-IL-4,
10 ug/ml)), Th2 (IL-4, 10 ng/ml; IL-2, 10 ng/ml; anti-IFNc,
10 ng/ml) or iTreg (TGFb, 10 ng/ml, Retinoic acid, 10 nM)
conditions in the presence or absence of OVA-pulsed irradiated
splenocytes as APC’s for seven days, as indicated.
Freshly isolated nTreg or in vitro generated iTreg cells were
washed and cultured with either IL-4 (10 ng/ml), IL-12/IFNy
(both at 10 ng/ml) or media only. Cells were harvested after
24 hours or supernatant was collected after 3 days. For adoptive
transfer experiments, recipient mice were given OVA (Sigma,
Grade V) via the trachea one day before adoptive transfer of 106
Th1 or Th2 cells. For intra-tracheal (i.t.) inoculation, mice were
anaesthetized with ketamine and medetomidine and given 20 ml of
OVA (10 mg) in PBS directly into the trachea. Recipient mice were
given OVA i.t. on day 1 and day 3-post transfer before analysis on
day 4. In some experiments, cells were isolated from recipient
mice, transfected as above, and either adoptively transferred with
newly generated Th1 or Th2 cells into a second recipient or used
in proliferation/suppression. For 2nd adoptive transfer experi-
ments, 106 newly generated Th1 or Th2 cells were co-transferred
with 106 isolated and transfected Treg cells from recipient mice.
Twenty-four hours after the OVA i.t., mice were anaesthetized
with pentobarbital. The trachea was cannulated and airspaces
lavaged with 500 ml of sterile PBS for cellular analysis. For
histopathological analysis lungs were removed, formalin (4%
paraformaldehyde in PBS) fixed embedded in paraffin and stained
with Hematoxylin and eosin (H&E). Inflammation was scored on
an arbitrary 1–4+ basis taking into account both the degree of
inflammation and its distribution. Local lymph nodes were
isolated, prepared into a single cell suspension and cultured with
OVA (10 mg/ml) for 3 days.
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ELISA
Cytokines were measured by ELISA using suppliers’ guidelines.
Capture and biotinylated detection antibodies for IL-4, IL-5, IL-
10, IFNc, IL-17A and IL-9 were from R&D Systems. The
concentration of analytes in the sample was determined from a
serial-fold diluted standard curve with OD read at 405 nm in an
ELISA reader.
Supporting Information
Figure S1 Number and direction of common regulated
genes in Lm- and Sm-Foxp3+ cells. 185 common genes that
were differentially regulated within Lm- Foxp3+ cells and Sm-
Foxp3+ cells, indicating up or down regulated expression.
(TIFF)
Figure S2 Isolation and transfection of primary Foxp3+
cells. Foxp3+ cells were isolated from the spleen or inflamed
tissue, as indicated, made into single cell suspensions (A), stained
and FACS sorted (B). Purified Foxp3 cells were transfected at
26105 cells per well with miRNA mimics or inhibitors with
BlockiT or SiGlo transfection indicators (C).
(TIFF)
Figure S3 Th1-Treg cells potently suppress Th1 and
Th2 cells in-vitro, while Th2-Treg cells only suppress
Th2 cells. Th2 or Th1 T effector (Teff, CD4+CD44+Foxp3gfp2)
and Treg (CD4+Foxp3gfp+) cells were isolated from the lungs of
recipient mice, as in Figure 4. Teff cells (104) were labeled with cell
trace violet and cultured alone, or in the indicated ratios with Th1-
Treg or Th2-Treg cells for 3 days (A–D). One of 2 individual
experiments shown. Freshly isolated Th1-Treg cells were trans-
fected with miR-10a mimics or Th2-Treg cells were transfected
with miR-182 inhibitors (E), as indicted. RNA was extracted after
24 hours and miRNA levels were quantified by RT-PCR.
(TIFF)
Figure S4 Treg cells from naı̈ve mice cannot suppress
pathogenic Th1 or Th2 Teff cells. Th1 (A) and Th2 (B) T
effector (Teff, CD4+CD44+Foxp3gfp2) cells were isolated from the
lungs of recipient mice, as in Figure 4 and Figure 5. As a control,
naı̈ve T cells (C) were also isolated from the spleen of OTII mice.
Naı̈ve Treg cells were isolated from naive mice. Teff or naı̈ve T
cells (104) were labeled with cell trace violet (Invitrogen) and
cultured alone, or in equal ratios (1:1) with mock transfected Treg
cells (B), Treg cells transfected with miR-10a mimics or Treg cells
transfected with miR-182 inhibitors, as indicated, for 3 days with
irradiated splenocytes (26105) and OVA (10 mg/ml). One of 2
individual experiments shown, with technical replicates shown in
the scatter plot.
(TIFF)
Figure S5 IL-4 regulates cMaf and miR-182, while IL-
12/IFNc regulate Creb and miR-10a expression in nTreg
and iTreg cells. In silco predicted Transcription factor binding
within the promoter of miR-182 and miR-10a using PWMSCAN
and TRANSFACv10.2. (A). FACS purified ex vivo nTreg or in
vitro generated and FACS purified iTreg cells (B) were stimulated
with IL-4 (10 ng/ml) or IL-12 (10 ng/ml)/IFNc (10 ng/ml) for
24 hours before RNA was extracted, and mRNA (C, D) or
miRNA (E, F) transcript abundance was determined by RT-PCR.
One of 2 individual experiments shown. * p-value,0.05 with data
expressed as mean 6SEM.
(TIFF)
Figure S6 nTreg or in vitro generated iTreg cells from
Foxp3rfp and Foxp3gfp mice do not differ in miR-182 or
miR-10 expression. Ex vivo isolated nTreg (A) and in vitro
generated iTreg cells (B) were FACS purified from Foxp3gfp or
Foxp3rfp reporter mice. RNA was immediately extracted and miR-
182 and mIR-10a levels were determined by RT-PCR, and
expressed relative to Foxp32 cells with data expressed as mean
6SEM.
(TIFF)
Figure S7 IL-4-regulated miR-182 and IL-12/IFNc-reg-
ulated miR-10a control IL-2 and IFNc production,
respectively. FACS purified ex vivo nTreg or in vitro generated
and FACS purified iTreg cells were stimulated with IL-4 (10 ng/
ml) or IL-12 (10 ng/ml)/IFNc (10 ng/ml) for 24 hours before
RNA was extracted and mRNA (A–E) transcript abundance
determined by RT-PCR. FACS purified nTreg and iTreg cells
were transfected with miR-182 inhibitors (E) or miR-10a mimics
(F) before treatment with IL-4 or IL-12/IFNc. Cells were
recovered after 24 hours for mRNA analysis or supernatants were
recovered after 3 days of culture for protein analysis (E). One of 2
individual experiments shown. * p-value,0.05 with data
expressed as mean 6SEM.
(TIFF)
Figure S8 Adoptive transfer system. One million Th1 or
Th2 polarised cells from C57BL/6 CD45.1 OTII RAG22/2 mice
were adoptively transferred into CD45.2 Foxp3gfp mice (Recipient
1) one day after i.t. OVA treatment. Recipient Mice were given 2
additional OVA treatments 1 and 3 days post transfer.
CD4+Foxp3gfp cells were isolated from the lungs of recipient mice
and either untreated, Mock transfected or transfected with
miRNA mimics or inhibitors (as in Figure S2). Fresh Th1 or
Th2 polarised cells from C57BL/6 CD45.1 OTII RAG22/2 mice
were generated and co-transferred with the treated CD4+Foxp3gfp
cells into a third mouse (Recipient 2), one day after OVA
challenge. Recipient 2 mice with treated with OVA i.t. 1 and 3
days post transfer and were anlaysed on day 4 post transfer.
(TIFF)
Table S1 Significantly differentially regulated genes in
Foxp3+ populations represented in Heat map (left table)
and in samples, as indicated (right 3 tables).
(PDF)
Table S2 Mapping of Deep Sequencing reads. Mapping of
data to SOLiD dataset, miRBase and the mouse genome. (A)
Uniquely mapped reads, (B) All mapped reads, (C) Representation
of other RNA species in dataset. Representative workflow of
mapping strategy. Sm = Schistosoma mansoni-derived Treg.
Lm = Leishmania major-derived Treg.
(PDF)
Table S3 Significantly differentially regulated miRNAs
in Foxp3+ populations. Fold change of significantly regulated
miRNAs.
(PDF)
Table S4 Candidate master regulatory miRNAs identi-
fied from Monte Carlo simulation.
(PDF)
Table S5 Predicted mRNA targets of miR-182 and miR-
10a identified from Monte Carlo analysis.
(PDF)
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